OMNICELL, INC.
About OMNICELL, INC.
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $1.2B
- Net income
- $2.1M
- Total assets
- $2.0B
- Market cap
- $2.0B
- Gross margin
- 42.5%
- Operating margin
- 0.4%
- Net margin
- 0.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.2B
- Cost of revenue
- $681.4M
- Gross profit
- $503.4M
- Operating expenses
- $498.3M
- Operating income
- $5.2M
- Income tax
- $9.3M
- Net income
- $2.1M
- EPS (basic)
- $0.04
- EPS (diluted)
- $0.04
Balance sheet
- Total assets
- $2.0B
- Current assets
- $680.1M
- Total liabilities
- $742.9M
- Current liabilities
- $476.6M
- Shareholders’ equity
- $1.2B
Cash flow
- Operating cash flow
- $127.3M
- Investing cash flow
- -$60.4M
- Financing cash flow
- -$218.3M
- Net cash flow
- -$147.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $2.0B
- P/E ratio
- 1048.8
- EPS (diluted)
- $0.04
- Shares outstanding
- 46.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 6, 2001
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $2.1M in FY2025.
- Revenue grew 5% from FY2021 to FY2025.
- Gross margin of 42.5%, net margin 0.2%.
- Trading 18% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 1048.8.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review OMNICELL, INC..
Write a review
News about OMNICELL, INC.
News & sentiment via Polygon.io
